Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update